(2S,3S,4R,5R)-5-[6-(环戊基氨基)嘌呤-9-基]-N-乙基-3,4-二羟基四氢呋喃-2-甲酰胺 | 110299-05-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 中文名称: (2S,3S,4R,5R)-5-[6-(环戊基氨基)嘌呤-9-基]-N-乙基-3,4-二羟基四氢呋喃-2-甲酰胺
• 英文名称: Selodenoson
• 英文别名: (2S,3S,4R,5R)-5-[6-(cyclopentylamino)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide
• CAS: 110299-05-3
• 化学式: C₁₇H₂₄N₆O₄
• 分子量: 376.4
• InChiKey: GWVQGVCXFNYGFP-PFHKOEEOSA-N

物化性质

• 熔点：
  95-101 °C
• 密度：
  1.68±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  134
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  ethyl (2S,3S,4R,5R)-3,4-diacetyloxy-5-(6-chloropurin-9-yl)oxolane-2-carboxylate 生成 (2S,3S,4R,5R)-5-[6-(环戊基氨基)嘌呤-9-基]-N-乙基-3,4-二羟基四氢呋喃-2-甲酰胺
  参考文献：
  名称：

  HAMILTON, HARRIET W.;PATT, WILLIAM C.

  摘要：

  DOI：

文献信息

• Method of treating atrial fibrillation or atrial flutter
  申请人：Gadgil Shrikant

  公开号：US20050009776A1

  公开（公告）日：2005-01-13

  The present invention relates to the use of N 6 -cyclopentyl-5′-(N-ethyl)carboxamidoadenosine (DTI-0009) or a pharmaceutically acceptable salt or ester thereof in the treatment of atrial fibrillation or atrial flutter in a human. Especially an acute attack of atrial fibrillation or atrial flutter is treated by the method of this invention.

  本发明涉及使用 N 6 -环戊基-5′-(N-乙基)羧氨基腺苷(DTI-0009)或其药学上可接受的盐或酯用于治疗人的心房颤动或心房扑动。本发明的方法尤其适用于心房颤动或心房扑动的急性发作。
• Controlled release formulation
  申请人：Aurora Jack

  公开号：US20050118262A1

  公开（公告）日：2005-06-02

  The present invention discloses a controlled release formulation suitable for oral administration comprising N 6 -cyclopentyl-5′-(N-ethyl)carboxamidoadenosine or a pharmaceutically acceptable salt or ester thereof incorporated in a controlled release matrix. The controlled release formulation of the invention is especially suitable for treating heart rhythm disturbances in a mammal.

  本发明公开了一种适用于口服的控释制剂，由 N 6 -环戊基-5′-(N-乙基)羧氨基腺苷或其药学上可接受的盐或酯并入控释基质中。本发明的控释制剂特别适用于治疗哺乳动物的心律紊乱。
• ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS
  申请人：Gahl William A.

  公开号：US20130109645A1

  公开（公告）日：2013-05-02

  Disclosed are a method of treating or preventing a disorder in a mammal comprising administering to the mammal an adenosine receptor agonist or an adenosine receptor antagonist, either alone or in combination, in an amount effective to treat or prevent medial vascular or joint capsule calcification. Disclosed are methods of detecting or diagnosing a vascular or joint capsule calcification disorder, as well as a nucleic acid comprising a mutation in one or more exons of human NT5E selected from the group consisting of Exon 3, Exon 5, and Exon 9.
• US6784165B1
  申请人：——

  公开号：US6784165B1

  公开（公告）日：2004-08-31
• [EN] CONTROLLED RELEASE FORMULATION<br/>[FR] FORMULATION A LIBERATION CONTROLEE
  申请人：ADERIS PHARMACEUTICALS INC

  公开号：WO2005025545A2

  公开（公告）日：2005-03-24

  The present invention discloses a controlled release formulation suitable for oral administration comprising N6-cyclopentyl-5’-(N-ethyl)carboxamidoadenosine or a pharmaceutically acceptable salt or ester thereof incorporated in a controlled release matrix. The controlled release formulation of the invention is especially suitable for treating heart rhythm disturbances in a mammal.